# Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

> **NCT06754865** · — · NOT_YET_RECRUITING · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 1140 (estimated)

## Conditions studied

- Acute Exacerbation of Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Xiyanping injection+ antibiotic
- **DRUG:** Antibiotic

## Key facts

- **NCT ID:** NCT06754865
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 1140 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754865, "Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06754865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*